TrialNature medicine2026

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Ida Aronchik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.